Navigation Links
US HIFU Partners with Riverside Research Institute to Add Cancer Targeting Technology to HIFU Treatment
Date:2/9/2010

CHARLOTTE, N.C., Feb. 9 /PRNewswire/ -- US HIFU, a worldwide leader in the development, distribution and use of minimally invasive high intensity focused ultrasound (HIFU) technologies, announced today its exclusive partnership with Riverside Research Institute (RRI) to develop and test an ultrasonic method of prostate imaging and treatment that combines advanced tissue-type imaging with ultrasound energy from the Sonablate® 500 medical device.  The objective of this modality is to more reliably detect and evaluate cancerous tissue and make treating only the cancerous prostatic tissue instead of the entire gland possible.  This capability will take prostate cancer diagnosis and treatment to an exciting new level. Once the combined technologies are clinically validated, this advanced tissue-typing technology will become a standard feature in the Sonablate device.

"We are continually refining the HIFU procedure and have been researching focal therapy, which simply means targeting and treating the cancerous prostatic tissue instead of the entire prostate," said US HIFU CEO Steve Puckett, Jr. "We are extremely pleased to join forces with Riverside Research Institute because of what it can mean for patient care. This partnership may lead to an unprecedented capability to find the cancer and treat it with HIFU."

Sonablate HIFU, currently under FDA investigation in the U.S., treats the diseased prostate with the power of ultrasound by delivering extreme heat in rapid-fire succession to miniscule targets throughout the prostate so that the prostate is ablated, a process similar to the sun's rays burning a leaf when directed through a magnifying glass.

Ernest Feleppa, Ph.D., RRI Research Director said, "We are very excited about the advances in prostate cancer treatment that this partnership makes possible.  The current lack of a reliable means of imaging prostate tumors typically requires treatment of prostate cancer to involve the entire gland.  By incorporating a method of imaging tumors within the prostate, we will be able to take full advantage of the precise ability of HIFU to target only the diseased region, which will spare healthy tissue, retain gland function and minimize toxic side effects.  This capability, which will be realized in a single integrated ultrasound device, represents a major breakthrough in prostate cancer treatment."

Dr. Feleppa will describe tissue-type imaging and what it can mean for cancer treatment at the Third International Symposium on Focal Therapy and Imaging of Prostate and Kidney Cancer, taking place in Washington, D.C. from February 24-27.

About US HIFU, LLC

US HIFU, LLC is a privately held healthcare company focused on treating primary and recurrent prostate cancer using HIFU, a minimally invasive outpatient procedure. US HIFU was founded in 2004 and is headquartered in Charlotte, N.C. Additional information can be found at www.ushifu.com.

About the Sonablate® 500

The Sonablate® 500 is a minimally invasive medical device that utilizes ultrasound energy to destroy tissue within the body. It was developed by Focus Surgery, Inc. and is manufactured in part by Misonix, Inc. (Nasdaq: MSON), which also holds distribution rights in Europe. Takai Hospital Supply Ltd. distributes the Sonablate® 500 in Southeast Asia. The Sonablate® 500 is not approved for use in the U.S. The Sonablate® 500 remains investigational in the U.S. and is being studied for the treatment of prostate cancer in clinical trials in the U.S. FDA has made no decision as to the safety or efficacy of the Sonablate® 500 for the treatment of prostate cancer.

About Riverside Research Institute

Riverside Research Institute transitions science and technology from the abstract to reality, from theory to the laboratory, and from the laboratory to the field. Headquartered in New York City, Riverside Research Institute, a 501(c )(3) organization, has six major offices across the United States.  Its New York office houses its biomedical engineering laboratories—the Frederic L. Lizzi Center for Biomedical Engineering.  Biomedical research at the Institute emphasizes advanced biomedical-ultrasound technology for imaging and treating disease.  Additional information is available at http://www.rri-usa.org.

SOURCE US HIFU, LLC

RELATED LINKS
http://www.internationalhifu.com

'/>"/>

SOURCE US HIFU, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Prolifiq and viaLanguage Announce Partnership: Accelerate the Use of Localized Content by Sales Teams
2. HealthWarehouse.com and PrimaryCareOne Form Partnership to Provide Low Cost Prescription Medications to Patients
3. MarketsandMarkets Partners With IIR USA for Their Event Advanced Biomarker Strategies in Oncology Drug Development
4. MarketsandMarkets Partners with the 9th Annual ePharma Summit to be Held on February 8 -10, 2010
5. PRA International Formalizes Partnership with Oncopartners and IBPC
6. CareFusion Signs Exclusive Partnership Agreement With Minimally Invasive Devices to Distribute FloShield Laparoscopic Technology
7. Medstrat Partners with Major Orthopedic Company
8. Medco Partners with AmeriCares to Rush Donated Medicines to Help Victims of the Haiti Earthquake
9. Henry Schein Works With Supplier Partners to Earmark $1 Million in Health Care Supplies for Haiti Earthquake Relief
10. Spotsylvania Regional Medical Center Partners with TeleHealth Services for Integrated Patient Education
11. VetCentric Partners With Hills Pet Nutrition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017  Akcea Therapeutics, a subsidiary ... to the company,s board of directors: ... Partners. Mr. Gabrieli will serve as chairman of the board ... former chief commercial officer of Forest Laboratories. ... Biolink Partners. "We are excited to ...
(Date:3/28/2017)... SAN FRANCISCO , March 28, 2017 ... is expected to reach USD 8.0 billion by 2025, ... Inc. The increasing incidence of infectious diseases and cancer ... for use in disease diagnosis over the coming years. ... the usage of autologous and allogenic stem cell therapy, ...
(Date:3/27/2017)... LONDON , March 27, 2017 ... require to better understand Eli Lilly and its partnering interests ... Alliance since 2010 report provides an in-depth insight into the ... companies. On demand company reports are prepared upon ... deal and company data. The report will be ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... ... Paul Yost, will begin serving as new board chair for Orange County health ... will serve the remainder of soon-to-be former chair Mark Refowitz’s term, which runs ...
(Date:3/28/2017)... Appleton, WI (PRWEB) , ... March 28, 2017 ... ... how self-funded health plans work, the Self-Funding Success website has recently developed and ... about Self-Funded Health Plans ” was created based on common inquiries the site’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric ... Inc. is thrilled to offer the recently FDA-approved Obalon Balloon System to his ... to SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. Dr. Liu ...
(Date:3/28/2017)... Albertson, NY (PRWEB) , ... March 28, 2017 , ... Oily skin is a common ... with Advanced Dermatology has a lot to offer to the discussion of dealing ... good news is that there are many home remedies that can help remove the oily ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep apnea ... with or without a referral. Sleep apnea is often left untreated because patients are ... headaches and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep ...
Breaking Medicine News(10 mins):